Combination or sequential therapies targeting metabolism in melanoma can help counter BRAF inhibitor resistance in melanoma, preventing the re-activation of BRAF downstream effectors or countering the shift towards oxidative phosphorylation associated with BRAF inhibition. This evidence concerns the gene BRAF and melanoma.